Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment

Hypertension

Volumn 49, Issue 5, 2007, Pages

  Schlaich, Markus P ^a   Lambert, Elisabeth A ^a   Sobotka, Paul A ^b   Lambert, Gavin W ^a   Esler, Murray D ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b Ardian Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; NORADRENALIN; PLACEBO;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG MECHANISM; ESSENTIAL HYPERTENSION; HUMAN; HYPERACTIVITY; HYPERTENSION; LETTER; MORBIDITY; MORTALITY; NERVE CONDUCTION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; SYMPATHETIC NERVE; SYMPATHETIC TONE; ADRENERGIC SYSTEM; CHRONIC DISEASE; DRUG EFFECT; KIDNEY DISEASE; NOTE; PATHOPHYSIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; HUMANS; HYPERTENSION; KIDNEY DISEASES; SYMPATHETIC NERVOUS SYSTEM;

EID: 34247859072     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.087908     Document Type: Letter

References (5)

1. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-1359.
2. Neumann J, Ligtenberg G, Klein IH, Boer P, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension. 2007;49:506-510.
3. Krum H, Lambert E, Windebank E, Campbell DJ, Esler M. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. Am J Physiol Heart Circ Physiol. 2006;290:H1706-H712.
4. Schlaich MP, Kaye DM, Lambert E, Hastings J, Campbell DJ, Lambert G, Esler MD. Angiotensin II and norepinephrine release: interaction and effects on the heart. J Hypertens. 2005;23:1077-1082.
5. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J Hypertens. 2001;19:2241-2250.